ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2927

Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis

Priyanka Vashisht1, Jessica M. Dorschner2, Mark A. Jensen3, Beverly Chrabot4, Theresa Wampler Muskardin5, Marlena Kern6, Tetrad Investigators7, ABCoN Consortium8, S. Louis Bridges Jr.9,10, P.K. Gregersen11 and Timothy B. Niewold2, 1Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 4Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 5Div of Rheumatology, Mayo Clinic, Rochester, MN, 6North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, 7AL, 8NY, 9University of Alabama at Birmingham, Birmingham, AL, 10Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 11The Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, interferons, Rheumatoid arthritis (RA), treatment and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA).  Previous studies have suggested that circulating type I interferon (IFN) levels may predict treatment response to TNF-α inhibitors and other biological agents in RA.  Prediction of likely responders prior to initiating therapy would represent a major advance in biological treatment strategies for RA.

Methods We studied a test set of 32 RA patients from the ABCoN registry and a validation set of 80 RA patients from the TETRAD registry.  All subjects had serum available prior to treatment with a TNF-α inhibitor.  In the test set, only those with a good response or no response at 14 weeks by EULAR criteria were included.  In the validation set, subjects were included from the EULAR good, moderate, and non-response categories defined at 12 weeks post-treatment.  Pre-treatment total serum type I IFN activity as well as IFN-α vs. IFN-β activity were measured using a functional reporter cell assay. 

Results In the test set, an increased ratio of IFN-β/IFN-α >1.3 in the pre-treatment serum sample was associated with lack of response by EULAR criteria at 14 weeks (p=0.009), and a receiver-operator curve supported a ratio of 1.3 as the optimal cut-off.  Similarly, higher IFN-β/IFN-α ratio was positively correlated with higher DAS score at 14 weeks in the test set (Spearman’s rho= 0.57, p=0.0075).  In the validation set, subjects with an IFN-β/IFN-α ratio >1.3 were significantly more likely to have non-response by EULAR criteria at 12 weeks (p=0.0035), and no patient with this ratio or greater achieved a good response.  In meta-analysis, IFN-β/IFN-α ratio >1.3 was a strong discriminator of good response vs. non-response at 12-14 weeks (OR = 18.0, p=7.4×10-5), and also a significant predictor of non-response vs. either moderate or good response at 12-14 weeks (OR = 4.34, p=0.0014).  Anti-CCP antibody titer and mechanism of action (mAb vs etanercept) of TNF-α inhibitor did not influence this relationship. 

Conclusion  Increased pre-treatment serum IFN-β/IFN-α ratio was strongly associated with non-response to TNF-α inhibition by EULAR criteria at 12-14 weeks.  This blood test may be useful in making treatment decisions using TNF-α inhibitors in RA and other diseases.


Disclosure:

P. Vashisht,
None;

J. M. Dorschner,
None;

M. A. Jensen,
None;

B. Chrabot,
None;

T. Wampler Muskardin,
None;

M. Kern,
None;

T. Investigators,
None;

A. Consortium,
None;

S. L. Bridges Jr.,
None;

P. K. Gregersen,
None;

T. B. Niewold,

Janssen Pharmaceutica Product, L.P., EMD Serono,

2,

Biogen Idec, EMD Serono,

5.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-serum-interferon-betaalpha-ratio-predicts-response-to-tumor-necrosis-factor-alpha-inhibition-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies